Processa Pharmaceuticals, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Robert Michael Floyd. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Robert Michael Floyd has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PCSA / Processa Pharmaceuticals, Inc. Chief Operating Officer 82,267
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Robert Michael Floyd. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases PCSA / Processa Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in PCSA / Processa Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-06-22 PCSA Floyd Robert Michael 2,000 7.0292 100 140.5840 14,058 1

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCSA / Processa Pharmaceuticals, Inc. Insider Trades
Insider Sales PCSA / Processa Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in PCSA / Processa Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCSA / Processa Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Robert Michael Floyd as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-02-10 2023-02-09 4 PCSA Processa Pharmaceuticals, Inc.
Common Stock
A - Award 10,000 82,267 13.84 0.80 8,000 65,814
2022-10-11 2022-10-06 4 PCSA Processa Pharmaceuticals, Inc.
Common Stock
F - Taxes -4,163 72,267 -5.45
2022-10-11 2022-10-06 4 PCSA Processa Pharmaceuticals, Inc.
Common Stock
M - Exercise 12,500 76,430 19.55
2022-08-23 2022-08-16 4 PCSA Processa Pharmaceuticals, Inc.
Common Stock
G - Gift -7,000 63,930 -9.87
2022-04-11 2022-04-01 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 247,841 302,766 451.24
2022-04-04 2022-03-31 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 10,715 37,781 39.59
2022-04-04 2022-03-31 4 PCSA Processa Pharmaceuticals, Inc.
Common Stock
G - Gift -7,000 70,930 -8.98
2022-04-04 2021-11-01 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 4,286 27,066 18.81
2022-01-06 2021-09-30 4/A PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 6,024 16,058 60.04
2022-01-06 2021-12-31 4/A PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 6,722 22,780 41.86
2022-01-04 2021-12-31 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 6,722 6,722
2021-10-08 2021-10-06 4 PCSA Processa Pharmaceuticals, Inc.
Common Stock
F - Taxes -4,663 9,387 -33.19
2021-10-08 2021-10-06 4 PCSA Processa Pharmaceuticals, Inc.
Common Stock
M - Exercise 12,500 14,500 625.00
2021-10-04 2021-09-30 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 6,024 6,024
2021-07-09 2021-07-08 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 1,907 10,034 23.46
2021-07-09 2021-07-08 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 12,858 12,858
2021-07-09 2021-07-08 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 8,572 8,572
2021-06-22 2021-06-22 4 PCSA Processa Pharmaceuticals, Inc.
Common Stock
P - Purchase 2,000 28,000 7.69 7.03 14,058 196,818
2021-06-10 2021-06-08 4 PCSA Processa Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 8,127 8,127
2020-10-16 3 PCSA Processa Pharmaceuticals, Inc.
Common Stock
26,000
2020-10-16 3 PCSA Processa Pharmaceuticals, Inc.
Common Stock
103,851
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)